Investigating the effect of antiretroviral switch to tenofovir alafenamide on lipid profiles in people living with HIV.

Background: Whilst reporting improved renal and bone safety profiles, studies have noted changes in lipid profiles among people living with HIV (PLWH) receiving antiretroviral therapy (ART) switching away from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF). We aimed to characterize changes in lipids observed after switching to TAF-containing ART in a real-world setting.

Methods: A prospective study on PLWH enrolled in the UCD-ID Cohort study who switched to TAF-containing ART.